• Saved

A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up - Dermatology and Therapy

A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up - Dermatology and Therapy

Source : https://link.springer.com/article/10.1007/s13555-022-00778-y

Atopic dermatitis (AD) is a chronic pruritic skin disease that can have a profound negative impact on patients' quality of life, especially in cases of inadequate disease control. Dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, is approved in the United States for the treatment of moderate-to-severe AD in adults (≥ 18 years old) and in children (≥ 6 years old).


Conclusion: In summary, phase 3 clinical trials of dupilumab demonstrate that dupilumab provides a multidimensional benefit in patients ages 6 years and older with moderate-to-severe AD, with rapid and sustained improvements in AD signs and symptoms and an acceptable safety profile.

  • September 05, 2022
    This article helps to solidify that dupixent is an excellent first line medicine for moderate to severe AD. It is a go-to medicine in my practice. My experience is similar to what has been shown in the trials: minimal side effects and excellent efficacy for a majority of patients
  • September 04, 2022
    Indeed, we should feel very comfortable prescribing dupixent - minimal side effects and no lab monitoring needed - and now also approved for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies like corticosteroids or when those therapies are not advisable.